{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~22 mi. (Kryvyy Rih, Ukraine, +207 more cities)
facility
MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
city
~22 mi. (Kryvyy Rih, Ukraine, +190 more cities)
facility
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department
biomarker
ATM Loss, +27 more biomarkers
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~22 mi. (Kryvyy Rih, Ukraine, +45 more cities)
facility
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 1804)
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~98 mi. (Kropyvnytskyy, Ukraine, +158 more cities)
facility
LLC Ukrainian Center of Tomotherapy ( Site 2105)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~98 mi. (Kropyvnytskyy, Ukraine, +150 more cities)
facility
Ukrainian Center of Tomotherapy ( Site 1708)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~98 mi. (Kropyvnytskyy, Ukraine, +137 more cities)
facility
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 1451)
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~98 mi. (Kropyvnytskyy, Ukraine, +92 more cities)
facility
Ukranian Center of TomoTherapy ( Site 0140)
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~98 mi. (Kropyvnytskyy, Ukraine, +67 more cities)
facility
Ukrainian Center of Tomotherapy ( Site 1807)
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~98 mi. (Kropyvnytskyy, Ukraine, +145 more cities)
facility
Ukrainian Center of Tomotherapy ( Site 2206)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~98 mi. (Kropyvnytskyy, Ukraine, +115 more cities)
facility
Kirovograd Regional oncology Dispensary ( Site 1716)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~99 mi. (Antonivka, Ukraine, +163 more cities)
facility
Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council (
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types